Our goal is to become the premier digital healthcare accelerator to serve the needs of patients, providers, payers, and researchers.

Our innovative approach helps transform the discovery, development, and delivery of digital health solutions by harnessing novel data insights and accelerated methodologies. Ultimately, we help create a future in which patients are empowered to make healthy decisions about behaviors and habits, providers have the tools to help deliver care seamlessly and efficiently, and payers can support their members with evidence-based, cost-effective technology.

Digital Health Research and Insights

Dario Clinical & Economic Outcomes

ADA Poster: Impact of Digital Diabetes Solution on Glycemic Control in Adults With Type 2 Diabetes Mellitus in the United States: A Retrospective Cohort Study

This study applied a retrospective cohort study design with a non-user cohort, with a comparison between users and non-users.1

ADA Poster: Use of Digital Diabetes Solution Is Associated With Improved Glycemic Control Without Increased Risk of Severe Hypoglycemia in Adults With Type 2 Diabetes Mellitus in the United States: Retrospective Cohort Study

This study applied a retrospective cohort study design with a non-user cohort, with a comparison between users and non-users.2

ISPOR Poster: Comparison of All-Cause Healthcare Resource Utilization Rates Between Patients With Type 2 Diabetes Who Use a Digital Diabetes Solution Versus Non-Users: a 12-Month Retrospective Cohort Study

Diabetes is a chronic condition that affects millions of individuals in the United States and can amount to billions of dollars in estimated direct medical costs.3

ADA Poster: Effect of a Digital Diabetes Solution on All-Cause Healthcare Resource Utilization Charges for Patients With Type 2 Diabetes: A Retrospective Cohort Study

Digital healthcare technology that provides personalized interventions can reduce medical costs.4

Dario Summary Slide

Sanofi’s real-world studies in digital health compared user and non-user cohorts to clearly understand the potential clinical and economic impact of Dario’s diabetes management solution.5

White Paper: Transforming Chronic Disease Management With the Sanofi | Dario Digital Health Solution

Patients who are actively involved in their healthcare tend to incur 8.3% lower costs than those who are less engaged; with Dario, MedOne aims to find engagement across a multitude of means.6

Digital Health Insights

Digital Interventions for Self-Management of Type 2 Diabetes Mellitus: Systematic Literature Review and Meta-Analysis

Findings from this systematic literature review analyzed the impact of high-intensity coaching in digital interventions for the self-management of type 2 diabetes defined by the availability and level of personalization.7

Behavioral Engagement and Activation Model Study (BEAMS): A Latent Class Analysis of Adopters and Non-Adopters of Digital Health Technologies Among People With Type 2 Diabetes

This study reviews the confidence levels of individuals with type 2 diabetes of their self-management.8

A Roadmap to an Equitable Digital Diabetes Ecosystem

To establish a balanced and connected digital diabetes ecosystem, the authors of this paper proposed a roadmap with key milestones that need to be delivered along the way.9

 


 

Trust Building Mechanisms in Digital Healthcare Data Recording and Measuring for Adults With Type 2 Diabetes

Trust building was analyzed for user-centered digital healthcare launch strategies that focus on self-efficacy and balance.10

Patient and Physician Perspectives on the Use of a Connected Digital Ecosystem for Type 2 Diabetes Management: International Cross-Sectional Survey Study

Additional education around connected digital ecosystems may be needed.11

Contact a Sanofi Representative

Learn more about how Sanofi uses digital health solutions to help improve outcomes and reduce the costs of managing chronic conditions.

Intended for use with payers, formulary committees, or other similar entities for the purposes of population-based drug selection, coverage, and/or reimbursement decision-making. The links on this page are provided as resources only and do not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources on this topic may be available and should be investigated. Sanofi does not review or control the content of non-Sanofi websites.

 

References: 1. Thingalaya N, et al. Poster presented at: ADA 2023; June 23-26, 2023, CA, USA. 2. Thingalaya N, et al. Poster presented at: ADA 2023; June 23-26, 2023, CA, USA. 3. Wilson L, et al. Poster presented at: ISPOR 2023; May 7-10, 2023, MA, USA. 4. Wilson L, et al. Poster presented at: ADA 2023; June 23-26, 2023, CA, USA. 5. Data on file. Sanofi US. 6. Data on file. Sanofi US. 7. Kerr D, et al. J Med Internet Res. 2024;26:e55757. doi:10.2196/55757 8. Piette JD, et al. Transl Behav Med. 2024;14(8):491-498. doi:10.1093/tbm/ibae034 9. Kerr D, et al. Endocr Pract. 2023;29(3):179-184. doi:10.1016/j.eprac.2022.12.016 10. Liska J, et al. Poster presented at: ATTD 2023; Feb 22-25, 2023, Berlin, Germany. 11. Benito E, et al. Poster presented at: ATTD 2023; Feb 22-25, 2023, Berlin, Germany.